
As a specialized section, pharmaceutical news covers all aspects of the pharmaceutical industry, from policies and regulations, and market dynamics to scientific and technological innovation.
It provides readers with comprehensive, timely, and accurate information on the pharmaceutical industry. By focusing on the pharmaceutical news section, readers can better understand the development trends and market changes in the pharmaceutical industry, and provide useful references for corporate decision-making and personal health.
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive recommendation for the approval of toripalimab (brand name Lo···【more】
Article source: Captain MedicineRelease date: 2024-08-26Recommended: 675
On June 27, 2024, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use issued a favorable opinion recommending the approval of a marketing autho···【more】
Article source: Captain MedicineRelease date: 2024-08-19Recommended: 639
On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel, marking the first gene-engineered T-cell therapy approved for the treatment of solid tumors. Th···【more】
Article source: Captain MedicineRelease date: 2024-08-12Recommended: 600
On June 14, 2024, the US Food and Drug Administration (FDA) granted approval for blinatumomab (Blincyto, Amgen Inc.) to be used in the consolidation phase of multiphase chemotherap···【more】
Article source: Captain MedicineRelease date: 2024-08-07Recommended: 593
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. For patients with advanced or metastatic NSCLC, partic···【more】
Article source: Captain MedicineRelease date: 2024-08-05Recommended: 625
On June 26, 2024, the Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager,···【more】
Article source: Captain MedicineRelease date: 2024-08-01Recommended: 557
On June 27, 2024, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended a change to the marketing authorization terms for the dr···【more】
Article source: Captain MedicineRelease date: 2024-07-19Recommended: 693
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed countries (extended to July 1, 2033), Laos has been legally permitted to produce ge···【more】
Recommended:225Release date: 2026-08-05
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos have gradually entered the view of Chinese cancer and chronic disease patients due ···【more】
Recommended:240Release date: 2026-08-04
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rapid growth in its generic pharmaceutical industry in recent years. Lucius Pharmac···【more】
Recommended:282Release date: 2026-07-31
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital of Laos. The company was established in 2020, with its R&D and operational s···【more】
Recommended:206Release date: 2026-07-28
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Drug CompanyRelocation Background and Strategic ShiftLucius Pharmaceuticals was fo···【more】
Recommended:311Release date: 2026-07-24
In recent years, Laos has gradually become a major global supply source for generic drugs, leveraging the WTO-granted patent exemption for least-developed countries. Among them, Lu···【more】
Recommended:252Release date: 2026-07-22
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was established in 2020, with its headquarters located at No. 26, Thongmang Village···【more】
Recommended:264Release date: 2026-07-20
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operatio···【more】
Recommended:276Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos' generic drug industry is rooted in unique international rule dividends. As a U···【more】
Recommended:382Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease patients in China due to their significant price advantage. Leveraging the WTO pat···【more】
Recommended:232Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulation adopts a centralized "one ministry, one department" management mod···【more】
Recommended:305Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late but has developed rapidly in recent years. Relying on the WTO's patent waiver for least develope···【more】
Recommended:328Release date: 2026-07-09
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended:927Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended:868Release date: 2024-07-09

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643